Citius Pharmaceuticals Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Vanguard International High Dividend Yield ETF trades at $104.49. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VYMI | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $105.05 |
52-Week Low | $0.48 | $82.92 |
Enterprise Value | $16.23M | — |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.48, down slightly by 0.11% today. The technical outlook is bullish based on moving averages, with key support at $104 and resistance at $105. Recent news highlights strong institutional buying and its appeal to retirees seeking international dividend income, with the fund outperforming the S&P 500 over the past five years.
The ETF offers a compelling income play with a 3.4% dividend yield and an 8.86% five-year dividend CAGR, supported by bullish analyst sentiment. Risks include currency fluctuations from international exposure and broader market volatility, but its diversification and high yield provide a defensive stance amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →